SANTA ANA, Calif., April  09, 2026  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) (&#34;NKGen&#34; or the &#34;Company&#34;), a clinical-stage biotechnology company focused on the development and commercialization of innovative

NKGN

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

NKGen to Showcase Troculeucel Data at Upcoming Neuroimmunology Summit

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SANTA ANA, Calif., April  09, 2026  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) (&amp;#34;NKGen&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biotechnology company focused on the development and commercialization of innovative</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>NKGen Biotech will present crucial data on its investigational NK cell therapy, troculeucel, at the Neuroimmunology Drug Development Summit on April 16, 2026. The data highlights potential efficacy in treating neurodegenerative diseases, which could enhance investor confidence and positively influence stock performance depending on reception.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>NKGen will present troculeucel data at Neuroimmunology Summit.</li><li>Focus is on neurodegenerative diseases like Alzheimer&#039;s and FTD.</li><li>Early-stage studies show reductions in neuroinflammatory signals.</li><li>WHO approved the nonproprietary name &#039;troculeucel&#039; for SNK01.</li><li>Data presentation scheduled for April 16, 2026, at 11 AM ET.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>World Health Organization (WHO)</strong>: Approved the nonproprietary name for NKGen&#039;s drug, enhancing credibility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments as it pertains to upcoming data presentations that could influence investor sentiment and market performance based on clinical results.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive reception of troculeucel data could lead to significant stock price gains.</li><li>Loss of confidence from negative feedback may trigger sell-off risks.</li><li>New partnerships or funding announcements could boost market position.</li><li>Broader acceptance of NK cell therapies may enhance long-term valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>NKGen will present on April 16, 2026.</li><li>Troculuec is designed for Alzheimer&#039;s and frontotemporal dementia.</li><li>The WHO has approved the nonproprietary name &#039;troculeucel&#039;.</li><li>Data indicate reductions in neuroinflammatory signals in studies.</li><li>NKGen specializes in natural killer cell therapeutics.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a bullish position on NKGN ahead of the data presentation.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">SANTA ANA, Calif., April  09, 2026  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/quote/NKGN">NKGN</a>) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8<sup>th</sup> Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.</p>  <p align="justify">NKGen's Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel's use in neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia ("FTD"). The presentation will include an overview of the Company&#39;s expanding mechanistic dataset, including evidence that troculeucel selectively targets autoreactive T cells and may modulate key neuroinflammatory pathways implicated in disease progression.</p>  <p align="justify">Dr. Song will also review clinical observations from early-stage studies, including encouraging biomarker trends and reductions in neuroinflammatory signals measured in cerebrospinal fluid. These data build on previously reported preclinical and clinical findings and further support troculeucel's potential as a differentiated, cell-based approach to treating neurodegenerative disorders with high unmet medical need.</p> <table style="border-collapse: collapse; width:99%; border-collapse:collapse ;"><tr><td colspan="2" style="max-width:10%; width:100.048%; min-width:10%;"><strong><u>NKGen Presentation Details</u></strong><strong>:<br></br><br></br></strong></td></tr><tr><td style="width:12.2369%;"><strong>Title</strong>:</td><td style="width:87.8109%;">Exploring Natural Killer Cell Immunotherapeutics to Reduce Neuroinflammation in Alzheimer's &amp; FTD </td></tr><tr><td style="width:12.2369%;"><strong>Track:</strong></td><td style="width:87.8109%;">Emerging Clinical Viability of Neuro-immune Targeting</td></tr><tr><td style="width:12.2369%;"><strong>Date &amp; Time:</strong></td><td style="width:87.8109%;">Thursday, April 16, 2026, at 11:00 AM ET</td></tr></table> <p align="justify"><br></br>The Neuroimmunology Drug Development Summit is a scientific and industry conference focused on the development of therapies targeting neuroinflammation in neurodegenerative diseases, bringing together academic and industry experts to discuss emerging research and therapeutic approaches.</p>  <p align="justify">A copy of the presentation will be made available on the Company's website under the <a href="https://www.globenewswire.com/Tracker?data=z18qxlakZCQj4ZNnH9aHRWkri6VtGw6wggycgg47gRkF9-IMrjAURcGNGeK-sr7ER_DzdJDs9d4-ismcTcFiBbNBc8iAG5LiAic6zWHkCeBmJKjNWEWWwaqpelT_qIWl4kE3Ta6mCMOud2i9wHUWXA==" rel="nofollow" target="_blank">Scientific Publications</a> section, once the event has concluded. Additionally, previously disclosed scientific data on troculeucel for neurodegenerative disease can be accessed on the same page. For the latest updates on our clinical trials and regulatory announcements, please visit the Company's <a href="https://www.globenewswire.com/Tracker?data=gj3pjxER9pAQAMa6n3V_-icfvL8AxWql37HHLnyTTOfY8A-070aGAjeT4v9E1PnjPCg_FZJy0Jhoocve4EZsiw==" rel="nofollow" target="_blank">News</a> page.</p>  <p align="justify"><strong>About Troculeucel</strong><br></br>Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ("INN") for SNK01 assigned by the World Health Organization ("WHO"). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market.</p>  <p align="justify"><strong>About NKGen Biotech</strong><br></br>NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=6LvyRPXcOr6f4gunpQdC0lknMjtGq77vVVOsbJ1ns8fsyJ_MbHkZ2P3C6BeMQDWU6B51I8nVOZed9x2w12jrF0BmFJtC8n86q_FzWliF7Q8=" rel="nofollow" target="_blank">www.nkgenbiotech.com</a>.</p>  <p align="justify"><strong>Forward-Looking Statements </strong><br></br>Statements contained in this press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "could", "continue", "expect", "estimate", "may", "plan", "outlook", "future" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's anticipated timing and content of its filings with the U.S. Securities and Exchange Commission (the "SEC") and other public disclosures; the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. Additional risks include uncertainties related to the Company's acquisition of a majority interest in NKGen Biotech Korea Co., Ltd., including risks regarding the future performance of NKGen Biotech Korea Co., Ltd.'s business, the Company's ability to successfully integrate NKGen Biotech Korea Co., Ltd.'s operations, personnel, and technologies, potential challenges in realizing expected synergies and cost savings, and risks that the Company may not achieve the anticipated strategic, financial, or operational benefits of the acquisition on the expected timeline or at all. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a> and on the Company's website under the subheading "Investors—Financial and Filings". Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</p>  <p align="justify"><strong>Internal Contact:</strong><br></br>Denise Chua, MBA, CLS, MLS (ASCP)<br></br>SVP, Corporate Affairs<br></br>949-396-6830<br></br><a href="https://www.globenewswire.com/Tracker?data=Q4VMhLq2wgD-iqvv0rPL5N0iH3hAwexJ4lcZjDi9mqLa_ymX-aVazpiKOyIrWEJyw9cTlsiGku1M76L00330MusdcuCMglg_KsRQg9v7scM=" rel="nofollow" target="_blank">dchua@nkgenbiotech.com</a></p>  <p align="justify"><strong>External Contacts:</strong><br></br>Kevin Gardner<br></br>Managing Director<br></br>LifeSci Advisors, LLC<br></br><a href="https://www.globenewswire.com/Tracker?data=e87G1VfAWHbwaHaNNB0P1UzSUHx6TOgyPZ-vhbrj5lKNiiIsU7vHKM0fCKqb8IREO7YXXUEVoyxS1lJ8Mc6xWbboI-5iY5TQEIdrjaewATmkJBbiqJiLMJmpchdLxjlm" rel="nofollow" target="_blank">kgardner@lifesciadvisors.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3ODczNiM3NTA0MjQzIzUwMDA3MDg1OA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YzkxYTVmMmYtZmFkNC00MzNiLWFhZTMtNDAwYzYxOWVjZmIxLTUwMDA3MDg1OC0yMDI2LTA0LTA5LWVu/tiny/NKGen-Biotech-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/756e1bcd-a22f-4971-bf36-2be2aa012814"><img src="https://ml.globenewswire.com/media/756e1bcd-a22f-4971-bf36-2be2aa012814/small/nkgen-biotech-rgb-jpg.jpg" border="0" width="150" height="44" alt="Primary Logo"></img></a></p>

NKGen Biotech will present crucial data on its investigational NK cell therapy, troculeucel, at the Neuroimmunology Drug Development Summit on April 16, 2026. The data highlights potential efficacy in treating neurodegenerative diseases, which could enhance investor confidence and positively influence stock performance depending on reception.

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News